CCL2 and cholangiocarcinoma: In the CCA cohort, CCL2‐positive expression and accumulation of TAMs, as indicated by CD68‐positive expression, were both associated with poor prognosis, and patients with EHF(+)/CCL2(+) or EHF(+)/CD68(+) had the worst prognosis (Figure 7J).